Navigation Links
GE Medical Systems Signs Clinical Trial with National Cancer Institute

WAUKESHA, WI. - GE Medical Systems, has signed a clinical trial agreement with the Cancer Imaging Program of the National Cancer Institute (NCI) for multi-site clinical trials of 18F-Fluorothymidine (FLT) as an agent for positron emission tomography (PET), applied to the managemen......

Full article >>> By using agents like FLT that can specifically image proliferation and other aspects of tumor biology, we can look at tumors before and soon after treatment to determine reliably whether a given therapy will be effective or not," Thrall said. "The idea is to personalize therapy by using PET imaging of the cancer to choose the right treatment and enable the patient to avoid inappropriate therapy." ......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 11/24/03


Related biology technology :

1. Medical College receives $377K to study brain disease
2. Medical College team creates website for tracking flu
3. Medical College receives $1.4M cancer grant
4. Medical technology firm lands $100K federal grant
5. Doyle outlines spending for Medical College, UWM
6. Medical College lands $8.1M grant to detect bird flu, bioterror agents
7. Medical College dedicates $140M research facility
8. Dunn to step down as Medical College dean
9. Medical College team seeks stem cell patent
10. Medical College part of $5M cancer study
11. Medical College secures $9.7M research grant
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... ... pharmaceutical research and development (R&D), today announced the launch of Data ... interpretation for the rapidly evolving field of precision medicine. , Data ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):